Nanosonics Ltd (ASX: NAN) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Nanosonics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$1.02 billion
P/E Ratio
88.81
Dividend Yield
0.00%
Shares Outstanding
303.00 million
Earnings per share
0.042
Dividend per share
N/A
Year To Date Return
-18.86%
Earnings Yield
1.13%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Nanosonics Ltd (ASX: NAN)
Latest News
⏸️ Investing
9 juicy health care stocks to add to your portfolio: Part 1
⏸️ Investing
3 big reasons to buy Nanosonics Ltd.
⏸️ Investing
Here's why these 3 stocks are soaring higher today
⏸️ Investing
Is Nanosonics Ltd. still a buy after today's big jump?
⏸️ Investing
Here's why these 4 stocks are flying higher today
⏸️ Investing
These 3 stocks could shoot the lights out
⏸️ Investing
4 stocks soaring on the ASX today
⏸️ Investing
Reporting season update: Should you buy these 3 small-cap superstars?
⏸️ Investing
Can Nanosonics Ltd join the likes of Cochlear Limited and Resmed Inc?
⏸️ Investing
7 speculative stocks deserving your attention
Frequently Asked Questions
-
No, Nanosonics Ltd does not pay dividends at this stage.
-
Nanosonics Ltd listed on the ASX on 17 May 2007.
NAN ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Nanosonics Ltd
Nanosonics Ltd (ASX: NAN) is an Australian healthcare company specialising in infection prevention.
The company has developed and commercialised an automated disinfection technology, the trophon device. Nanosonics says it represents the first major innovation in high-level disinfection for ultrasound probes in more than two decades and is fast becoming the global standard of care for ultrasound probe disinfection. The company also manufactures and distributes other related technologies.
Nanosonics is based in Sydney with sales offices in the US and Europe.
NAN Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 15 Nov 2024 | $3.37 | $0.02 | 0.60% | 291,543 | $3.36 | $3.39 | $3.31 |
| 14 Nov 2024 | $3.35 | $0.05 | 1.52% | 326,762 | $3.30 | $3.36 | $3.29 |
| 13 Nov 2024 | $3.30 | $-0.02 | -0.60% | 362,449 | $3.31 | $3.31 | $3.21 |
| 12 Nov 2024 | $3.32 | $0.04 | 1.22% | 398,938 | $3.30 | $3.32 | $3.21 |
| 11 Nov 2024 | $3.28 | $0.03 | 0.92% | 206,482 | $3.26 | $3.34 | $3.24 |
| 08 Nov 2024 | $3.25 | $0.01 | 0.31% | 184,982 | $3.20 | $3.28 | $3.18 |
| 07 Nov 2024 | $3.24 | $0.04 | 1.25% | 188,402 | $3.20 | $3.24 | $3.18 |
| 06 Nov 2024 | $3.20 | $0.03 | 0.95% | 239,506 | $3.21 | $3.23 | $3.12 |
| 05 Nov 2024 | $3.17 | $0.01 | 0.32% | 152,176 | $3.11 | $3.19 | $3.11 |
| 04 Nov 2024 | $3.16 | $-0.04 | -1.25% | 280,089 | $3.21 | $3.22 | $3.14 |
| 01 Nov 2024 | $3.20 | $0.00 | 0.00% | 290,578 | $3.15 | $3.22 | $3.12 |
| 31 Oct 2024 | $3.20 | $-0.02 | -0.62% | 292,896 | $3.17 | $3.22 | $3.17 |
| 30 Oct 2024 | $3.22 | $-0.03 | -0.92% | 371,397 | $3.25 | $3.27 | $3.18 |
| 29 Oct 2024 | $3.25 | $-0.06 | -1.81% | 662,798 | $3.32 | $3.36 | $3.20 |
| 28 Oct 2024 | $3.31 | $-0.02 | -0.60% | 472,711 | $3.30 | $3.38 | $3.26 |
| 25 Oct 2024 | $3.33 | $0.02 | 0.60% | 265,633 | $3.36 | $3.36 | $3.30 |
| 24 Oct 2024 | $3.31 | $-0.05 | -1.49% | 280,421 | $3.35 | $3.36 | $3.30 |
| 23 Oct 2024 | $3.36 | $-0.07 | -2.04% | 229,775 | $3.41 | $3.44 | $3.34 |
| 22 Oct 2024 | $3.43 | $-0.11 | -3.11% | 340,360 | $3.51 | $3.51 | $3.40 |
| 21 Oct 2024 | $3.54 | $0.02 | 0.57% | 383,365 | $3.51 | $3.55 | $3.49 |
| 18 Oct 2024 | $3.52 | $-0.11 | -3.03% | 365,823 | $3.58 | $3.62 | $3.52 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 01 Oct 2024 | Michael Kavanagh | Exercise | 286,885 | $1,058,605 |
Exercise of options.
|
| 01 Oct 2024 | Michael Kavanagh | Exercise | 72,781 | $268,561 |
Conversion of securities.
|
| 01 Oct 2024 | Michael Kavanagh | Issued | 9,446 | $34,855 |
Exercise of options.
|
| 01 Oct 2024 | Michael Kavanagh | Expiry | 256,494 | $946,462 |
As advised by the company. Lapsed
|
| 01 Oct 2024 | Michael Kavanagh | Issued | 72,781 | $268,561 |
Conversion of securities.
|
| 12 Sep 2024 | Larry Marshall | Buy | 20,000 | $71,873 |
On-market trade.
|
| 07 Jun 2024 | David Fisher | Sell | 100,000 | $303,769 |
On-market trade.
|
| 06 Jun 2024 | Michael Kavanagh | Sell | 90,000 | $274,151 |
On-market trade.
|
| 22 Mar 2024 | Marie McDonald | Buy | 18,606 | $49,999 |
On-market trade.
|
| 01 Mar 2024 | Larry Marshall | Buy | 25,000 | $68,182 |
On-market trade.
|
| 29 Feb 2024 | Michael Kavanagh | Issued | 385,140 | $1,051,432 |
Issue of securities. 14,06,324 Rights
|
| 28 Feb 2024 | Steven Sargent | Buy | 36,460 | $99,742 |
On-market trade.
|
| 16 Feb 2024 | Michael Kavanagh | Issued | 44,054 | $131,280 |
Issue of securities. 10,21,184 Rights
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Lisa Margaret McIntyre | Non-Executive Director | Dec 2019 |
Dr McIntyre executive background is in strategy, particularly in the areas of medical technology and healthcare, with many years as a partner at L.E.K. Consulting in the US and Australia, where she led the Asia Pacific Health practice. She is also member of the Risk committee and Chair of Innovation and Development Committee.
|
| Dr Larry Marshall | Non-Executive Director | Oct 2023 |
Dr Marshall is a technology innovator, physicist, and business leader. During his 26 years in the United States, Dr Marshall co-founded six companies in a range of markets including medical device which went public. Over the past 30 years, he has served as CEO/MD of six companies, and Chairman of four. He was MD, then co-Chairman of Arasor which he took public in 2006. He is also member of the Innovation and Development Committee.
|
| Mr Michael Kavanagh | Chief Executive OfficerManaging Director | Jul 2012 |
Mr Kavanagh has more than 29 years of international commercial experience in the healthcare market, having held local, regional and global roles in medical device and pharmaceutical industries. Before joining Nanosonics, he was Senior Vice President of Global Marketing for the medical device company Cochlear Ltd, a position he held for more than 10 years.
|
| Ms Marie Elizabeth McDonald | Non-Executive Director | Oct 2016 |
Ms McDonald has background in corporate and commercial law, having practised for many years as a partner at Ashurst. Ms McDonald was Chair of the Corporations Committee of the Business Law Section of the Law Council of Australia (2012 to 2013) and was a member of the Australian Takeovers Panel from 2001 to 2010. She is also member of the Innovation and Development Committee.
|
| Mr Steven Andrew Sargent | Non-Executive DirectorNon-Executive Chairman | Jul 2016 |
Mr Sargent's career included 22 years at General Electric, where he gained multi-industry, international experience leading businesses in industries including healthcare, energy and financial services across the USA, Europe and Asia Pacific. Mr Sargent has been a Non-Executive Director of Origin Energy Limited and is also a Non-Executive Director of Ramsay Healthcare Limited (since December 2021). He is also member of the Risk and Innovation and Development Committee.
|
| Dr Tracey Leigh Batten | Non-Executive Director | Sep 2023 |
Dr Batten brings over 30 years of experience in the healthcare sector gained in non-executive and executive roles, and medical practitioner and clinical roles. Dr Batten was CEO of Imperial College Healthcare NHS Trust in the UK, St Vincent's Health Australia, Eastern Health and Dental Health Services Victoria. She is also member of the Risk Committee and Innovation and Development Committee.
|
| Mr Matthew Carbines | General CounselCompany Secretary | May 2023 |
-
|
| Jason Burriss | Chief Financial Officer |
-
|
|
| Sunny Pillai | Chief Information Officer |
-
|
|
| Matthew Lipscombe | Chief Marketing Officer |
-
|
|
| Rod Lopez | Chief Operating Officer (COO) and Regional President APAC |
-
|
|
| David Morris | Chief Strategy Officer (CSO) and Regional President APAC |
-
|
|
| Steven Farrugia | Chief Technology Officer |
-
|
|
| Matthew Carbines | General CounselCompany Secretary |
-
|
|
| Ronan Wright | Regional President for Europe & Middle East |
-
|
|
| Ken Shaw | Regional President for the United States Canada and Latin America |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 51,277,573 | 16.92% |
| Citicorp Nominees Pty Limited | 50,339,477 | 16.61% |
| J P Morgan Nominees Australia Pty Limited | 39,860,096 | 13.16% |
| BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 14,993,564 | 4.95% |
| BNP Paribas Noms Pty Ltd | 14,088,824 | 4.65% |
| National Nominees Limited | 12,429,010 | 4.10% |
| UBS Nominees Pty Ltd | 12,018,963 | 3.97% |
| Mr Maurie Stang | 8,429,534 | 2.78% |
| Mr Bernard Stang | 6,862,564 | 2.26% |
| Mr Steve Kritzler | 6,489,737 | 2.14% |
| Australian Foundation Investment Company Limited | 5,715,556 | 1.89% |
| Mirrabooka Investments Limited | 2,840,511 | 0.94% |
| HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> | 2,534,549 | 0.84% |
| Dr Harry Hirschowitz | 2,139,090 | 0.71% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 1,697,770 | 0.56% |
| First Samuel Ltd Acn 086243567 <Anf Its Mda Clients A/C> | 1,373,622 | 0.45% |
| Certane Ct Pty Ltd <Nanosonics Eet A/C> | 1,206,695 | 0.40% |
| Citicorp Nominees Pty Limited <143212 Nmmt Ltd A/C> | 1,054,295 | 0.35% |
| Powerwrap Limited <Escala Sma Trading A/C> | 919,357 | 0.30% |
| Mr Evan Philip Clucas & Ms Leanne Jane Weston <Kuranga Nursery Super A/C> | 908,378 | 0.29% |
